Discovering The Potential of TEX28 as A Drug Target and Biomarker

Target Name: TEX28

NCBI ID: G1527

TEX28

Discovering The Potential of TEX28 as A Drug Target and Biomarker

TEX28 (MrX99) is a drug target and a biomarker that is being studied for its potential in treating various diseases, including cancer. It is a protein that is expressed in various tissues and cells in the body, including the brain, and has been shown to play a role in several cellular processes.

One of the main things that makes TEX28 an interesting drug target is its role in the regulation of cell division. The team that studied it found that TEX28 helps to control the number of cells that divide in the brain, which is important for the development and progression of many diseases, including cancer.

Another potential mechanism by which TEX28 may work as a drug target is its role in the regulation of blood vessel formation. The team that studied it found that TEX28 helps to control the growth and development of blood vessels, which is important for many diseases, including heart disease and diabetes.

In addition to its potential as a drug target, TEX28 has also been shown to be a potential biomarker. The team that studied it found that TEX28 levels are elevated in the brains of people with certain types of cancer, which could be used as a diagnostic marker for these diseases.

Overall, the team that studied TEX28 found that it is a promising drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand its potential and to develop safe and effective treatments.

Protein Name: Testis Expressed 28

The "TEX28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TEX28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets